Author: Lynne Taylor

The US Food and Drug Administration and the European Medicines Agency have both reported high levels of new drug approvals in 2014.

The National Institute for Health and Care Excellence (NICE) is reviewing its guidance on the use of five drugs, to decide whether or not they should be recommended as treatment options for ovarian cancer that has returned after previous treatment with chemotherapy.

The European Commission has approved IMS Health’s plans to acquire part of France-based Cedegim SA’s customer relationship management and strategic data business, but with conditions.

A new app has been launched which tells US consumers exactly which product is the right one to buy to treat their cold and flu symptoms.

NHS England has announced new steps to accelerate innovation in new treatments and diagnostics in 2015/16, including “inviting interested manufacturers that are prepared to contribute to the expansion of the Commissioning through Evaluation programme and the related Early Access to Medicines programme.”“We will aim to accelerate the cost-effective and affordable deployment of technologies and drugs, in light of the government’s Medicines and Medical Technology Review.